ApexOnco Front Page Recent articles 14 March 2025 Sutro calls time on folate At long last luvelta-T is shelved, and Sutro seeks a new focus. 13 March 2025 Ono takes on Takeda in polycythemia vera The Japanese group licenses sapablursen from Ionis for $280m. 4 October 2024 Roche expands in KRAS GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF. 2 October 2024 BeiGene tries where others failed The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants. 2 October 2024 The month ahead: October’s upcoming events Approval decisions loom for Opdivo and Lumakras, and earnings season starts again. 2 October 2024 AbbVie has Met phase 3, again The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development. 1 October 2024 Gritstone has a mountain to climb with Granite The group is persevering with Granite, but funds might be hard to come by. 30 September 2024 Regor’s selective approach attracts Roche For $850m up front Roche gets to challenge Pfizer. Load More Recent Quick take Novocure’s brain mets win comes with caveats 28 March 2024 Syndax menin inhibitor gets its big day 27 March 2024 After zolbetuximab investors look for a Claudin18.2 encore 26 March 2024 Another false dawn for Nkarta 22 March 2024 NextCure doubles down on Lair 22 March 2024 Again, Keytruda and PARP fail to lynk 21 March 2024 Innate gets a new lacutamab blow 21 March 2024 BioNTech has some cancer convincing to do 20 March 2024 New Breyanzi approval comes at a timely moment for Allogene 18 March 2024 Takeda ploughs a lonely CD38 furrow 14 March 2024 Load More Most Popular